Latest Neurology News

Page 2 of 12
Invex Therapeutics reported promising preclinical findings on Exenatide’s effects in a human Alzheimer's disease model, alongside a steady cash position and reduced operating outflows in Q3 FY26.
Ada Torres
Ada Torres
24 Apr 2026
Alterity Therapeutics has unveiled fresh Phase 2 data revealing ATH434’s ability to slow functional decline in Multiple System Atrophy patients, measured by the novel MuSyCA scale. This reinforces the drug’s disease-modifying potential ahead of pivotal Phase 3 trials.
Ada Torres
Ada Torres
22 Apr 2026
Compumedics maintains robust sales momentum but faces FY26 revenue timing challenges due to MEG installation delays and a cautious Somfit D rollout. The company expects solid year-on-year growth and positions for improved execution in FY27.
Ada Torres
Ada Torres
21 Apr 2026
Argent BioPharma has finalized the acquisition of CannPal Animal Therapeutics, securing a Phase 3 veterinary epilepsy asset with near-term commercial prospects and an option to acquire the Neuvis® drug delivery platform, enhancing its neurological portfolio and U.S. market ambitions.
Ada Torres
Ada Torres
13 Apr 2026
Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals has broadened availability of DAYBUE STIX, a new FDA-approved powder formulation of trofinetide for Rett syndrome, in the US. Early caregiver feedback and expert consensus highlight its potential role in personalised patient care.
Ada Torres
Ada Torres
8 Apr 2026
AdAlta’s BZDS1901 CAR-T therapy shows remarkable tumour shrinkage and complete responses in advanced mesothelioma patients, doubling expected outcomes and paving the way for higher dosing and expanded trials.
Ada Torres
Ada Torres
1 Apr 2026
Alterity Therapeutics has secured encouraging regulatory feedback from the FDA on its ATH434 Phase 3 program for Multiple System Atrophy, marking a critical step towards pivotal trial initiation.
Ada Torres
Ada Torres
30 Mar 2026
Argenica Therapeutics has secured a nearly $4 million R&D tax incentive rebate for FY25, strengthening its cash position as it prepares for a pivotal Phase 2b trial of its neuroprotective peptide ARG-007.
Ada Torres
Ada Torres
17 Mar 2026
Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals is seeking a re-examination of the European Medicines Agency’s refusal to approve trofinetide for Rett syndrome, aiming to overturn the setback and bring the treatment to European patients.
Victor Sage
Victor Sage
3 Mar 2026
Argent BioPharma reported a significantly reduced half-year loss of A$2.9 million, progressing a strategic acquisition to bolster its CannEpil drug pipeline and securing up to A$11 million in new funding.
Ada Torres
Ada Torres
27 Feb 2026
Neurotech International reports a dramatic reduction in half-year losses alongside significant clinical and regulatory progress for its lead cannabinoid therapy NTI164. The company also strengthens its cash position through a $4 million placement and a $4.7 million R&D tax refund.
Ada Torres
Ada Torres
26 Feb 2026
Neurotech International has reported positive long-term safety results for its lead drug candidate NTI164, bolstering its path towards regulatory approval and chronic use in paediatric neurological disorders.
Ada Torres
Ada Torres
23 Feb 2026